This study aimed to estimate incidence, cost per episode of care, and US population burden of cervical intraepithelial neoplasia (CIN).
For women continuously enrolled in a US health plan from January 1, 1999 to December 31, 2004, medical claims were used to identify potential CIN diagnosis. Presence and grade of CIN (CIN 1, CIN 2,3, or no CIN) were verified in medical records for a randomly selected subset (n = 254). Incidence, costs, and population burden were calculated.
Annual incidence for CIN 1 and CIN 2,3 was 1.6 and 1.2 per 1,000 women, respectively. Incidence was highest among women aged 21 to 30 years (3.3 and 3.6 per 1,000) and women aged 31 to 40 years (2.9 and 2.7 per 1,000). Costs per episode of care were higher for CIN 2,3 ($1,634 vs $1,084). Estimated annual burden per 1,000 US women was $1,059 for CIN 1 and $1,803 for CIN 2,3.
We estimate that 412,000 women in the United States are diagnosed with CIN annually, with an associated cost of approximately $570 million.
There are more than 400,000 women in the United States diagnosed with cervical intraepithelial neoplasia annually, with an associated cost of approximately $570 million.
1i3 Innovus, Eden Prairie, MN; 2Merck & Co., Inc., North Wales; and 3Merck & Co., Inc., West Point, PA
Reprint requests to: Henry J. Henk, PhD, i3 Innovus, 12125 Technology Dr, Eden Prairie, MN 55344. E-mail: email@example.com
This study was conducted by i3 Innovus, an Ingenix company, at 12125 Technology Dr, Eden Prairie, MN, in collaboration with Merck & Co., Inc.
Support for this study was provided by Merck & Co., Inc.